Making Alzheimer’s Biomarkers More Accessible

Join this 60-minute live webinar exploring practical advances in blood-based biomarker testing for Alzheimer’s disease (AD), with a focus on scalable and accessible quantitation of the optimal combination of biomarkers.

Despite rapid growth in AD biomarker research, it is not always clear which targets are the most meaningful and which measurement system best serves a given application. Quantitation methods range from highly specialized platforms requiring significant capital investment, to simpler approaches with lower sensitivity.

This session will introduce a new cost-effective and sensitive (sub-pg/mL) biomarker detection platform and present findings on an AD 5-plex biomarker panel on well-characterized clinical samples. Preliminary data on an eMTBR-tau243 and BD pTau-217 duplex available for early-access will also be presented.

Through a structured webinar format combining expert presentation and moderated discussion, participants will explore:

• Considerations and tradeoffs for selecting biomarker quantitation methods
• Deep-dive into scalable ultrasensitive detection without capital equipment
• The rational for targeted biomarker panels, including why pTau-217, Aβ42, Aβ40, NfL, and GFAP were selected.
• Evaluate targeted biomarker panel performance in well-characterized clinical samples

Designed to support scientific exchange and practical understanding, this session will provide a first look at evolving data and its potential implications for research and clinical workflows.

Faculty

Chair: Marissa Lee, PhD, Director of Applications, Taudia
Speaker: Noah Elder, Director of R&D, Taudia

This webinar is delivered in collaboration with Taudia.